Pharmaceutical companies have significantly increased investments in traumatic brain injury (TBI) drug development, although the late-stage clinical pipeline remains relatively limited. Nonetheless, multiple early-stage clinical trials are underway, with encouraging mid- and late-stage outcomes anticipated to broaden the traumatic brain injury therapeutic landscape in the years ahead. Historically, research efforts have primarily concentrated on moderate-to-severe TBIs, often overlooking concussive injuries or mild traumatic brain injuries (mTBI). This trend is now shifting, as clinical research into mild TBI is gaining traction, representing a pivotal change in how these injuries are diagnosed, treated, and managed over the long term.

Discover how AKUUGO® is reshaping chronic Traumatic Brain Injury care: https://www.delveinsight.com/sample-request/traumatic-brain-injury-market

DelveInsight’s Traumatic Brain Injury Market Insights report provides an in-depth overview of current treatment approaches, emerging traumatic brain injury therapies, individual drug market shares, and the historical and forecasted market size from 2020 to 2034. The analysis covers the 7MM, including the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Key Takeaways from the Traumatic Brain Injury Market Report

DelveInsight’s analysis estimates the traumatic brain injury market size at USD 1.3 billion across the 7MM in 2024.

Among these regions, the United States dominated the market in 2024, accounting for approximately 85% of total revenue, followed by Japan, which is expected to witness notable growth during the forecast period (2025–2034).

In July 2024, SanBio’s AKUUGO became the world’s first brain regeneration therapy to receive conditional approval in Japan for traumatic brain injury treatment.

Of the emerging therapies under evaluation, OXE103 is projected to secure the largest market share in the 7MM by 2034.

In 2024, the 7MM recorded nearly 4.3 million incident TBI cases, a figure projected to increase to 4.5 million by 2034. Across all regions, males represent a higher proportion of total TBI incident cases.

Key companies advancing innovative TBI therapies include Oxeia Biopharmaceuticals, Hope Biosciences, Oragenics, Cellvation, SHINKEI Therapeutics, SanBio, and others, all working toward introducing novel drugs into the TBI market.

Prominent pipeline candidates include OXE113, HB-AdMSCs, ONP-002, CEVA111, MR-301, AKUUGO, among others.

Stay updated on Japan-led clinical trials transforming Traumatic Brain Injury outcomes.

Traumatic Brain Injury Market Dynamics

The dynamics of the traumatic brain injury market are expected to evolve considerably over the coming years. Decades of technological advancement have resulted in highly sophisticated diagnostic tools, including advanced CT scanners and MRI systems, enabling faster and more precise detection of neurotrauma and providing critical insights during the crucial hours following injury.

In 2024, AKUUGO (Vandefitemcel; SB623) became the first cell-based therapy approved globally for traumatic brain injury, receiving conditional and time-limited approval in Japan for the treatment of chronic motor paralysis due to TBI under the country’s regenerative medicine regulatory pathway. AKUUGO is an allogeneic regenerative cell therapy composed of modified human bone marrow–derived mesenchymal stem cells designed to promote regeneration of damaged brain tissue through growth factor release (including FGF-2), immunomodulation, angiogenesis, and neuroprotective effects.

AKUUGO’s approval was supported by results from the global Phase II STEMTRA trial (NCT02416492), a randomized, double-blind, surgical sham-controlled study in patients with chronic motor deficits secondary to TBI, which demonstrated meaningful motor function improvement at six months with an acceptable safety profile. Following approval, a post-marketing clinical study (jRCT2033240263) has been initiated in Japan to further evaluate the long-term efficacy and safety of intracerebral AKUUGO implantation in chronic TBI patients with motor paralysis. This study is currently in the pre-recruitment stage.

SanBio has also aligned with the US FDA on the design of a planned Phase III trial for chronic motor paralysis due to TBI, with regulatory planning and trial preparations underway as of late 2025. Continued data collection and partial regulatory adjustments are being pursued in Japan to gradually lift distribution restrictions while meeting post-marketing requirements.

AKUUGO has received multiple regulatory recognitions highlighting its therapeutic potential, including Sakigake designation (April 2019), priority review (January 2022), and orphan regenerative medicine designation (June 2020) from Japan’s MHLW, as well as RMAT designation (September 2019) from the US FDA and ATMP designation (April 2019) from the EMA.

Additionally, multiple investigational therapies are being evaluated for TBI, and it is anticipated that these treatments will significantly shape the market during the forecast period. Rising awareness of the “silent epidemic” of mild TBI, the expected launch of more effective therapies, and improved diagnostic practices for concussions are all likely to drive market expansion across the 7MM. Nearly 90% of individuals experience mild TBI, yet effective treatment options remain scarce for civilian, athletic, and military populations. Collaborative efforts among developers, investors, and academic institutions are accelerating progress toward addressing this unmet need.

Despite these opportunities, certain challenges may restrain market growth. Approximately 30% of concussion patients suffer from persistent post-concussion symptoms and long-term complications, a prevalence that remains underrecognized in clinical practice. Moreover, there are no FDA-approved therapies for acute concussion, with rest and gradual return to activity continuing as the standard of care.

Learn about innovative cell therapies and neuroprotective strategies in Traumatic Brain Injury.

Traumatic Brain Injury Treatment Market

Medication management in traumatic brain injury is complex yet critically important, reflecting the intricate nature of brain function and the many unanswered questions that persist. While foundational principles guide pharmacological management, their implementation has become increasingly challenging due to healthcare system limitations, particularly those related to reimbursement policies and constrained rehabilitation timelines.

TBI treatment typically involves a multidisciplinary approach combining acute medical care, rehabilitation, and long-term support, tailored according to injury severity. Interventions may range from cognitive rehabilitation therapies to surgical procedures such as bilateral decompressive craniotomies. Currently, treatment often relies on off-label use of multiple drug classes aimed at symptom control, with high discontinuation rates.

In Japan, alongside regenerative approaches, investigator-led pharmacological strategies are also being explored. Notably, Perampanel, an approved anti-epileptic drug, is being evaluated in an academic, multicenter Phase II clinical trial (PEACE-TBI; jRCTs031250067) for its potential role in reducing secondary neuronal injury following TBI. Perampanel acts as an AMPA receptor antagonist, aiming to limit excitotoxic damage caused by excessive glutamate signaling after brain injury. The study enrolls adult patients with mild-to-moderate TBI and assesses neurological recovery using the Glasgow Outcome Scale–Extended at 90 days, underscoring Japan’s active academic contribution to TBI research.

To learn more about FDA-approved drugs for traumatic brain injury, visit @ Traumatic Brain Injury Treatment

Traumatic Brain Injury Pipeline Therapies and Key Companies

Pipeline candidates include OXE103 (Oxeia Biopharmaceuticals), HB-AdMSCs (Hope Biosciences), ONP-002 (Oragenics), CEVA101 (Cellvation), MR-301 (SHINKEI Therapeutics), and AKUUGO (SanBio), among others.

OXE103 is a synthetic analog of human ghrelin capable of crossing the blood–brain barrier and restoring metabolic and energy balance following concussion. HB-AdMSCs are adipose-derived mesenchymal stem cells being studied for chronic neuroinflammation in severe TBI. ONP-002 is a first-in-class intranasal neurosteroid under development for mild TBI, with Phase II studies planned in Australia and the US.

In Japan, AKUUGO represents the most advanced therapy, supported by completed Phase II data, an ongoing post-marketing study, and planned Phase III global development, positioning it as a cornerstone of the evolving TBI treatment landscape.

Recent Developments in the Traumatic Brain Injury Market

  • March 2025: Oragenics submitted its Investigator’s Brochure to support a Phase II trial of ONP-002 in Australia.

  • February 2025: SanBio confirmed successful production yields for the second commercial manufacturing run of AKUUGO.

  • February 2025: Oxeia Biopharmaceuticals announced plans to initiate Phase IIb trials of OXE103 later in 2025.

  • February 2025: Oragenics entered a strategic partnership with BRAINBox Solutions, a leader in multimodal TBI diagnostics.

  • January 2025: SanBio signed a manufacturing agreement with JCR Pharma for AKUUGO production.

Discover more about traumatic brain injury drugs in development @ Traumatic Brain Injury Clinical Trials

Traumatic Brain Injury Overview

Traumatic brain injury occurs when the brain sustains damage from a sudden blow or jolt to the head, commonly resulting from motor vehicle accidents, falls, sports injuries, or violent incidents. Injury severity ranges from mild concussions to severe, long-lasting neurological impairment. The immediate damage sustained at the time of trauma is referred to as the primary injury, which may affect localized regions or the entire brain. Even in the absence of skull fractures, rapid brain movement within the skull can cause bruising, bleeding, or tearing of neural tissue.

TBI symptoms vary by severity. Mild TBI may involve brief or no loss of consciousness, along with headaches, dizziness, confusion, visual disturbances, fatigue, sleep changes, mood alterations, and cognitive difficulties. Diagnosis relies on clinical evaluation, patient history, neurological examination, and imaging studies, as no single definitive diagnostic test exists. While loss of consciousness is common, particularly in severe cases, many individuals with mild TBI experience memory loss without losing consciousness.

Traumatic Brain Injury Epidemiology Segmentation

The epidemiology section of the report analyzes historical trends, current patient populations, and future forecasts across the 7MM. It examines multiple data sources and expert perspectives to identify drivers behind observed and anticipated patient trends.

The epidemiological assessment for 2020–2034 includes:

  • Total incident cases of TBI

  • Severity-based distribution of TBI cases

  • Gender-specific distribution of incident cases

  • Age-specific distribution of incident cases

Traumatic Brain Injury Market Report Metrics

Details

  • Study Period: 2020–2034

  • Coverage: 7MM [United States, EU4 (Germany, France, Italy, Spain), United Kingdom, and Japan]

  • Market CAGR: 10.9%

  • Market Size (2024): USD 1.3 Billion

Key Traumatic Brain Injury Companies
 Oxeia Biopharmaceuticals, Hope Biosciences, Oragenics, Cellvation, SHINKEI Therapeutics, SanBio, and others

Key Traumatic Brain Injury Therapies
 OXE113, HB-AdMSCs, ONP-002, CEVA111, MR-301, AKUUGO, and others

Scope of the Traumatic Brain Injury Market Report

  • Therapeutic Assessment: Current marketed and emerging TBI therapies

  • Market Dynamics: Forecast assumptions and overall market outlook

  • Competitive Intelligence: SWOT analysis and market entry strategies

  • Unmet Needs: KOL insights, analyst perspectives, and market access and reimbursement analysis


Related Reports

Traumatic Brain Injury Pipeline
Traumatic Brain Injury Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key TBI companies, including Oragenics, Inc., SHINKEI Therapeutics, Inc., AlzeCure, Algernon Pharmaceutical, Mitochon Pharmaceuticals, Hoth Therapeutics, Biomed Industries, Inc., BioArctic, Tiziana Life Sciences, TikoMed AB, Levolta Pharmaceuticals, Inc., Boulder BioScience, LLC, International Stem Cell Corporation, Revalesio Corporation, Teleport Pharmaceuticals, among others.

Traumatic Brain Injury Assessment Devices Market
Traumatic Brain Injury Assessment Devices Market Insights, Competitive Landscape and Market Forecast – 2032 report deliver an in-depth understanding of the market trends, market drivers, market barriers, and key traumatic brain injury assessment devices companies including BrainScope Company Inc, NOVASIGNAL CORPORATION, Compumedics Limited, Integra LifeSciences Corporation, Natus Medical Incorporated, InfraScan Inc, Dr. Langer Medical GmbH, RAUMEDIC AG, SyncThink Inc, Imeka, General Electric Company, pro2cool Tectrum, NanoDx, NIHON KOHDEN CORPORATION, Elekta, Advanced Brain Monitoring Inc, Boston Scientific Corporation, ESAOTE SPA, Koninklijke Philips N.V, Vivonics Inc., among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us
Kanishk Kumar
info@delveinsight.com
+14699457679
www.delveinsight.com